Company Encyclopedia
View More
name
TITAN SCIENTIFIC
688133.SH
Shanghai Titan Scientific Co., Ltd. engages in the provision of laboratory products and supporting services for scientific researchers and quality control personnel. The company offers scientific research reagents, special chemicals, scientific research instruments and consumables, laboratory construction, and scientific research information services. It serves universities, hospitals, research institutes, government agencies and R&D companies, as well as various fields, such as biomedicine, new materials, new energy, energy conservation and environmental protection, food and daily chemicals, analysis and testing, and intelligent manufacturing.
1.968 T
688133.SHMarket value -Rank by Market Cap -/-

Financial Score

07/11/2025 Update
C
Specialty ChemicalsIndustry
Industry Ranking110/153
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE0.52%D
    • Profit Margin0.55%C
    • Gross Margin22.46%D
  • Growth ScoreD
    • Revenue YoY-8.28%D
    • Net Profit YoY38.03%B
    • Total Assets YoY0.55%C
    • Net Assets YoY0.25%C
  • Cash ScoreB
    • Cash Flow Margin18156.85%A
    • OCF YoY-8.28%D
  • Operating ScoreC
    • Turnover0.54C
  • Debt ScoreC
    • Gearing Ratio41.14%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    TITAN SCIENTIFIC plans to invest CNY 29 million to subscribe to the seventh phase of the Relay Fund

    TITAN SCIENTIFIC announced that it will invest 29 million yuan to subscribe for the seventh phase of the Relay Fund, aiming to promote the company's strategic development and business expansion. By collaborating with professional investment institutions, TITAN SCIENTIFIC hopes to optimize its industrial layout, acquire industry resources and technical support, and drive future strategic investments and mergers and acquisitions to facilitate business development and ecosystem construction. The Relay Fund primarily invests in early-stage technology startups in areas such as new materials and scientific services

    Zhitong·
    SH
    688133
    -0.33%
    Zhitong·
    SH
    688133
    -0.33%

    TITAN SCIENTIFIC: Net profit in the first half of 2025 increased by 91.55% year-on-year

    TITAN SCIENTIFIC announced that in the first half of 2025, operating revenue was 1.219 billion yuan, a year-on-year decrease of 12.70%. Net profit was 9.7652 million yuan, a year-on-year increase of 91.55%

    Zhitong·
    SH
    688133
    -0.33%
    Zhitong·
    SH
    688133
    -0.33%

    The Chinese pharmaceutical industry is turning to local suppliers for reagent procurement, seeking to reduce costs and shorten delivery times

    Chinese pharmaceutical R&D companies are turning to local suppliers for reagent procurement to reduce costs and shorten delivery times. Due to the increase in import tariffs caused by the U.S. trade war, the market share of Western suppliers such as Thermo Fisher Scientific and Merck has been affected. Industry executives indicate that there will be greater reliance on domestic companies such as TITAN SCIENTIFIC and Vazyme Biotechnology in the future. It is expected that the import value of laboratory and diagnostic reagents in China will slightly decrease to USD 5.76 billion in 2024

    Reuters·
    SH
    688105
    +0.31%
    SH
    688133
    -0.33%
    US
    MRK
    +0.58%
    Reuters·
    SH
    688105
    +0.31%
    SH
    688133
    -0.33%
    US
    MRK
    +0.58%

    TITAN SCIENTIFIC plans to acquire 100% equity of ASL Company for 55.85 million yuan

    TITAN SCIENTIFIC plans to acquire 100% equity of Apollo Scientific Ltd. for approximately 55.85 million yuan. This transaction will enhance the company's overseas sales channels, enrich its product line, and promote the implementation of its overseas strategy. The target company has a diverse range of chemical products, and the transaction will help improve the company's overseas business capabilities and profitability while optimizing procurement costs

    Zhitong·
    SH
    688133
    -0.33%
    Zhitong·
    SH
    688133
    -0.33%

    Cathay Securities and Haitong Securities: Policy dividends drive the accelerated domestic substitution in the upstream of scientific research and pharmaceuticals, focusing on core targets such as TITAN SCIENTIFIC

    Guotai Junan released a research report pointing out that the upstream of scientific research and pharmaceuticals, as an important component of strategic emerging industries, is being driven by both policy and market forces. The government continues to introduce supportive policies to promote domestic substitution, especially in the field of biomedicine. Key recommendations include TITAN SCIENTIFIC, Aladdin, and NANOMICRO as core targets, with expectations for a rapid increase in the domestic substitution rate

    Zhitong·
    SH
    688690
    +0.66%
    SH
    688133
    -0.33%
    SH
    688179
    +0.31%
    Zhitong·
    SH
    688690
    +0.66%
    SH
    688133
    -0.33%
    SH
    688179
    +0.31%